Elacestrant
Elacestrant is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including ORSERDU. Available dosage form: tablet, film coated.
Drug details
- Generic Name
- Elacestrant
- Brand Names
- ORSERDU
- Application Number
- NDA217639
- Sponsor
- Stemline Therapeutics, Inc.
- NDC Codes
- 6
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ELACESTRANT
Indications and Usage
1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] , with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy ( 1 )